ContractCommon Stock Purchase Warrant • November 20th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
FIRST AMENDMENT TO GUARANTYGuaranty • November 20th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO GUARANTY AGREEMENT (the “Amendment”) is dated effective as of November 17, 2023 (the “Amendment Effective Date”), by and among American BriVision Corporation, a Delaware corporation (“American BriVision”), BioKey, Inc., a California corporation (“BioKey”), BioLite Holding, Inc., a Nevada corporation (“BioLite”), BioLite BVI, Inc., a British Virgin Islands corporation (“BioLite BVI, and, collectively with American BriVision, BioKey and BioLite, the “Companies”, and each, individually, a “Company”) and Lind Global Fund II LP (“Lind” and together with the Companies, the “Parties”).
ContractAbvc Biopharma, Inc. • November 20th, 2023 • Pharmaceutical preparations • Nevada
THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
FIRST AMENDMENT TO GUARANTOR SECURITY AGREEMENTGuarantor Security Agreement • November 20th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO GUARANTOR SECURITY AGREEMENT (the “Amendment”) is dated effective as of November 17, 2023 (the “Amendment Effective Date”), by and among American BriVision Corporation, a Delaware corporation (“American BriVision”), BioKey, Inc., a California corporation (“BioKey”), BioLite Holding, Inc., a Nevada corporation (“BioLite”), BioLite BVI, Inc., a British Virgin Islands corporation (“BioLite BVI, and, collectively with American BriVision, BioKey and BioLite, the “Companies”, and each, individually, a “Company”) and Lind Global Fund II LP (“Lind” and together with the Companies, the “Parties”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 20th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations • Nevada
This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of November 17, 2023, by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”), and Lind Global Fund II LP, a Delaware limited partnership (the “Investor”).
FIRST AMENDMENT TO SECURITY AGREEMENTSecurity Agreement • November 20th, 2023 • Abvc Biopharma, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO SECURITY AGREEMENT (the “Amendment”) is dated effective as of November 17, 2023 (the “Amendment Effective Date”), by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”) and Lind Global Fund II LP (“Lind” and together with the Company, the “Parties”).
